Effect of Tegaserod on Esophageal Pain Threshold, Regurgitation, and Symptom Relief in Patients With Functional Heartburn and Mechanical Sensitivity

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 4, 2006, Pages 442-450

  Rodriguez Stanley, Sheila ^a   Zubaidi, Sattar ^a   Proskin, Howard M ^b   Kralstein, Jeffrey R ^c   Shetzline, Michael A ^c   Miner Jr , Philip B ^a  

^a Oklahoma Foundation for Digestive Research   (United States)

^b Howard M Proskin & Associates Inc   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TEGASEROD;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY DISORDER; ARTICLE; BAROSTAT; BLOATING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESOPHAGUS PAIN; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEARTBURN; HUMAN; MALE; MECHANICAL STIMULATION; PAIN THRESHOLD; PRESSURE; RANDOMIZED CONTROLLED TRIAL; SATIETY; STATISTICAL SIGNIFICANCE; STIMULATION; SYMPTOMATOLOGY; THORAX PAIN; UPPER ABDOMINAL PAIN;

ADULT; AGED; COMPLIANCE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HEARTBURN; HUMANS; INDOLES; MALE; MIDDLE AGED; PAIN THRESHOLD; PATIENT SATISFACTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33645799910     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.01.014     Document Type: Article

References (41)

1. Lind T., Havelund T., Carlsson R., et al. The effect of omeprazole (OME) 20 mg and 10 mg daily on heartburn in patients with endoscopy negative reflux disease (ENRD). Gastroenterology 108 (1995) A151
2. Iskedjian M., and Einarson T. Meta-analysis of cisapride, omeprazole and ranitidine in the treatment of GERD. Clin Drug Invest 1 (1998) 9-18
3. Tolman K., Chandramouli J., and Fang J. Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Exp Opin Pharmacother 6 (2001) 1171-1194
4. DeVault K.R., and Achem S.R. Functional gastroesophageal reflux disease (GERD). Curr Treatment Options Gastroenterology 3 (2000) 295-302
5. Bate C.M., Griffin S.M., Keeling P.W., et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 10 (1996) 547-555
6. Galmiche J.P., Barthelemy P., and Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease. a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 11 (1997) 565-573
7. Lind T., Havelund T., Carlsson R., et al. Heartburn without esophagitis. efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 32 (1997) 974-979
8. Havelund T., Lind T., Wiklund I., et al. Quality of life in patients with heartburn but without esophagitis. effects of treatment with omeprazole. Am J Gastroenterol 94 (1999) 1782-1789
9. Kahrilas P.J., Quigley E.M., Castell D.O., et al. The effect of tegaserod (HTF 919) on oesphageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14 (2000) 1503-1509
10. Vigneri S., Termini R., Leandro G., et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333 (1995) 1106-1110
11. Buchheit K.H., and Buhl T. Prokinetic benzamides stimulate peristaltic activity in the isolated guinea pig ileum by activation of 5-HT4 receptors. Eur J Pharmacol 205 (1991) 203-208
12. 4 receptors in the isolated guinea pig ileum. Naunyn Schmiedebergs Arch Pharmacol 345 (1992) 387-393
13. 4 receptors to release the sensory transmitter CGRP and initiate the peristaltic reflex. Gastroenterology 106 (1994) A506
14. 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 115 (1998) 370-380
15. Foxx-Orenstein A.E., Kuemmerle J.F., and Grider J.R. The peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine is mediated by distinct mucosal 5-HT receptors. Gastroenterology 108 (1995) A600
16. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 15 (2001) 1745-1751
17. 4 receptors. Neurogastroenterol Motil 10 (1998) 459
18. Drossman A.D. Rome II. the functional gastrointestinal disorders. 2nd ed. (2000), Degnon Associates, McLean, VA
19. Fleiss J.L. The design and analysis of clinical experiments (1986), Wiley, New York Chapter 10
20. Fisher A.C., and Wallenstein S. Crossover designs in medical research. In: Buncher C.R., and Tsay J.Y. (Eds). Statistics in the pharmaceutical industry. 2nd ed (1994), Marcel Dekker, New York 193-206
21. Senn S. Crossover designs. In: Armitage P., and Colton T. (Eds). Encyclopedia of biostatistics (1998), Wiley, New York 1033-1049
22. Spiller R. Serotonergic modulating drugs for functional gastrointestinal diseases. Br J Clin Pharmacol 54 (2002) 11-20
23. Jiao H., and Xie P. Tegaserod inhibits noxious rectal distention induced response and limbic system c-FOS expression in rats with visceral hypersensitivity. World J Gastroenterol 10 (2004) 2836-2841
24. Sun Y., and Lou J. Effects of tegaserod on Fos, substance P and calcitonin gene-related peptide expression induced by colon inflammation in lumbarsacral spinal cord. World J Gastroenterol 10 (2004) 1830-1833
25. Schikowski A., Thewissen M., Mathis C., et al. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 14 (2002) 221-227
26. Coffin B., Farmachidi J.P., Rueegg P., et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distention in healthy subjects. Aliment Pharmacol Ther 17 (2003) 577-585
27. Tack J., Vos R., Janssens J., et al. Influence of tegaserod on proximal gastric tone and on the perception of gastric distention. Aliment Pharmacol Ther 18 (2003) 1031-1037
28. Kellow J., Lee O.Y., Chang F.Y., et al. An Asia-Pacific, double blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 53 (2003) 671-676
29. Muller-Lissner S., Koch G., Talley N.J., et al. Subject's global assessment of relief. an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 56 (2003) 310-316
30. Shah S.H., Jafri S.W., Gul M., et al. Efficacy and tolerability of tegaserod in constipation dominant irritable bowel syndrome. J Coll Phys Surg Pak 14 (2004) 21-24
31. Nyhlin H., Bang C., Elsborg L., et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 39 (2004) 119-126
32. Rodriguez-Stanley S., Ciociola A.A., Zubaidi S., et al. A single dose of Ranitidine 150 mg modulates esophageal acid sensitivity in patients with functional heartburn. Aliment Pharmacol Ther 20 (2004) 975-982
33. Fass R., Naliboff B., Higa L., et al. Differential effects of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 115 (1998) 1363-1373
34. Rodriguez-Stanley S., Zubaidi S., Ciociola A., et al. Wide spectrum of symptoms produced by barostat balloon distention of the esophagus in patients presenting with varied upper GI complaints. Am J Gastroenterol 97 (2002) A72
35. Rodriguez-Stanley S., Zubaidi S., Ciociola A., et al. Are patients with functional heartburn sensitive to both mechanical and chemical stimuli?. Am J Gastroenterol 97 (2002) A115
36. Bate C.M., Griffin S.M., Keeling P.W., et al. Reflux symptoms relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 10 (1996) 547-555
37. Galmiche J.P., Barthelemy P., and Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease. a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 11 (1997) 565-573
38. Lind T., Havelund T., Carlsson R., et al. Heartburn without esophagitis. efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 32 (1997) 974-979
39. Rodriguez-Stanley S., Zubaidi S., Ciociola A., et al. Barostat balloon distention of the esophagus. pressure-ramp vs. volume-step for determination of sensation and pain thresholds. Am J Gastroenterol 97 (2002) A73
40. Rodriguez-Stanley S., Zubaidi S., Proskin H., et al. Reliability of esophageal balloon distention and Bernstein measurements in patients with functional heartburn. Gastroenterology 126 (2004) A323
41. Muller-Lissner S., Koch G., Talley N.J., et al. Subject's global assessment of relief. an appropriate method to assess the impact of treatment in irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 56 (2003) 310-316